Supriya Lifescience Ltd.

SUPRIYA

₹670.95

-1.63% (-11.15)

Market Cap

₹5,418 Cr.

P/E

28.82

Key Ratios

Edit Ratio's

Market cap

5,418 Cr

28.82

Prom Holding

68.30 %

ROE (%)

14.61

ROCE (%)

20.23

Div Yield (%)

0.12

Sales

696 Cr

OPM (%)

37.44 %

Debt to Equity

Edit Ratio's

About

Supriya Lifescience Limited is a leading Indian manufacturer and supplier of active pharmaceut… Read more

Low

368

52W Range

High

842

Timeline

Key company specific updates

Company Timeline

Custom financial statementNew

Edit rows

In Rs. Cr.	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025

In Rs. Cr.	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Balance sheet
Net Block	75.45	88.78	91.01	84.68	97.99	100	190	262	310	448
Shareholders Funds	41.72	45.89	54.66	93.79	149	269	616	699	815	997
Profit & Loss
Operating Profit	19.66	17.13	21.96	64.43	98.38	173	214	128	176	261
Net Sales	171	184	213	278	312	391	530	461	570	696
Cash flow
Cash from Operating Activity	13.50	27.30	27.75	48.88	116	75.89	48.80	63.61	113	165
Net Capex (est)	18.24	9.59	4.71	-4.76	24.52	46.80	59.82	107	146	162
Ratios
ROCE (%)	22.36	20.39	25.34	56.99	56.93	57.24	33.29	17.47	20.23	—
ROE (%)	13.64	12.34	15.97	42.03	49.20	46.02	24.66	12.85	14.61	—

Forensics

6 Yes

Positive for this company

3 Neutral

Neutral for this company

6 No

Negative for this company

2 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Other Income

Other income is not affecting ratios of the company
Pledge

Promoters have not pledged a significant portion of their holding
Promoter Holding

Promoter has not sold any shares in the last 90 days
Depreciation Effect

Company is depreciating a lower percentage of assets. this is contributing to an increase in net profit
Revenue Recognition

Chances of aggressive revenue recognition - operating profit of company is not getting converted to cash and recievables rising faster than sales
Retail Holding

Unable to calculate due to limited data

Price & Performance

Working Capital

Working capital of the company seems to be under control
Debt

Company should not have issues servicing its debt
ROCE Strength

Roce of the company is consistently strong
Capex vs ROCE

Company has made significant capex which might be affecting its roce
Balance Sheet Strength

Balance sheet of the company is strong. but it might have issues paying it suppliers
Current vs Historic Valuation

Company is trading at a premium to 3yr historic valuations
ROE

Roe has decreased vs 10 year trend
Share price

Share price has increased over last 10 years but more due to rerating
Margin Stability

Margins of the company are volatile
Sales Growth

Unable to calculate due to limited data

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Therapeutic Area Break-Up

Peer Comparison

Peer Name	Latest Price	PE	Market cap(Cr)	Prom Holding(%)	YoY Qtly Sales(%)	ROCE (%)	ROE (%)
Supriya Lifescience	686	29.19	5,487	68.3	16.39	20.23	14.61
Acutaas Chemicals	1,099	56.45	8,960	35.96	37.13	14.79	6.35
Aether Industries	778.35	64.69	10,248	81.77	104.37	6.24	4
Aarti Drugs	452.15	23.81	4,004	55.48	9.16	16.7	13.38
Morepen Laboratories	63.01	28.73	3,391	35.65	10.11	15.61	11.35
Aarti Pharmalabs	877.8	28.43	7,745	44.29	11.47	16.83	12.34
IOL Chem & Pharma	97.07	26.79	2,707	52.62	4.73	11.74	8.34
Solara Active Pharma	610	0.00	2,646	37.94	-8.82	-17.43	-60.75

Corporate Actions

Consolidated Dividend

DATE

DETAILS

2024, Sep 20

Dividend Dividend of Rs.0.8 per share

2023, Sep 15

Dividend Dividend of Rs.0.6 per share

2022, Sep 01

Dividend Dividend of Rs.0.6 per share

FAQs on Supriya Lifescience Ltd. Business

What does Supriya Lifescience do?

Supriya Lifescience Limited is an Indian manufacturer and supplier of APIs, focusing on research and development. They offer a diverse range of niche APIs for different therapeutic segments and have a significant market presence globally.

Who are the competitors of Supriya Lifescience?

Supriya Lifescience major competitors are Acutaas Chemicals, Aether Industries, Aarti Drugs, Morepen Laboratories, Aarti Pharmalabs, IOL Chem & Pharma, Solara Active Pharma.
Market Cap of Supriya Lifescience is ₹5,487 Crs.
While the median market cap of its peers are ₹4,004 Crs.

Is Supriya Lifescience financially stable compared to its competitors?

Supriya Lifescience seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

View FAQ's On Shareprice

Cash Flow Machines

Actual Cash profits are more important than accounting profits. List of companies spitting out cash profits

Run Query

Global Leaders

Companies with a dominant global position in a product. Might be a sign of very strong moat.

Run Query

Small Cap Consistent Compounders

Small companies which consistently grow their sales , while maintaining healthy return on capital.

Run Query

Company Filing

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	May	Mar Jun Sep Dec	Jun Sep Dec
Investor Presentation	May	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar May Jun Aug Sep Dec	Jan Dec
Conference Call	Mar	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Dec
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Supriya Lifescience Ltd.

View the discussion on Valuepickr

A Deep Dive Into The Stock Of Supriya Lifescience | Inside Out - CNBC

SUPRIYA LIFESCIENCE LTD. DISCUSSION DOCUMENT – CVOCA CONFERENCE - Tushar Bohra

Ideas Dashboard

Timeline

Watchlist

Portfolio

Alerts

Research

Stock Screener

Market

Raw Material

Supriya Lifescience Ltd.

Supriya Lifescience Ltd.

Key Ratios

About

Timeline

Company Timeline

6 Yes

3 Neutral

6 No

2 No Data

Accounting & Shareholding

Contingent Liabilities

Other Income

Pledge

Promoter Holding

Depreciation Effect

Revenue Recognition

Retail Holding

Price & Performance

Working Capital

Debt

ROCE Strength

Capex vs ROCE

Balance Sheet Strength

Current vs Historic Valuation

ROE

Share price

Margin Stability

Sales Growth

Product Wise Break-Up

UNLOCK PREMIUM

Location Wise Break-Up

UNLOCK PREMIUM

Therapeutic Area Break-Up

UNLOCK PREMIUM

What does Supriya Lifescience do?

Who are the competitors of Supriya Lifescience?

Is Supriya Lifescience financially stable compared to its competitors?

Supriya Lifescience Ltd.

Supriya Lifescience Ltd.

Key Ratios

About

Timeline

Company Timeline

6 Yes

3 Neutral

6 No

2 No Data

Accounting & Shareholding

Contingent Liabilities

Other Income

Pledge

Promoter Holding

Depreciation Effect

Revenue Recognition

Retail Holding

Price & Performance

Working Capital

Debt

ROCE Strength

Capex vs ROCE

Balance Sheet Strength

Current vs Historic Valuation

ROE

Share price

Margin Stability

Sales Growth

Product Wise Break-Up

UNLOCK PREMIUM

Location Wise Break-Up

UNLOCK PREMIUM

Therapeutic Area Break-Up

UNLOCK PREMIUM

What does Supriya Lifescience do?

Who are the competitors of Supriya Lifescience?

Is Supriya Lifescience financially stable compared to its competitors?

SIGN UP FOR FREE